Neogenomics, Inc.
NEO
$10.10
-$0.44-4.18%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 11.65% | 12.06% | 13.89% | 15.27% | 16.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.65% | 12.06% | 13.89% | 15.27% | 16.07% |
| Cost of Revenue | 6.75% | 6.67% | 8.81% | 9.25% | 7.83% |
| Gross Profit | 18.60% | 19.92% | 21.52% | 24.83% | 30.18% |
| SG&A Expenses | 7.57% | 4.33% | 2.99% | 3.24% | 0.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.42% | 5.83% | 5.56% | 5.66% | 3.81% |
| Operating Income | 18.56% | 26.95% | 30.70% | 31.41% | 37.01% |
| Income Before Tax | 16.91% | 25.62% | 33.52% | 34.91% | 39.06% |
| Income Tax Expenses | 78.65% | 80.87% | 54.90% | 52.16% | 39.51% |
| Earnings from Continuing Operations | 10.51% | 19.31% | 31.50% | 32.95% | 39.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.51% | 19.31% | 31.50% | 32.95% | 39.02% |
| EBIT | 18.56% | 26.95% | 30.70% | 31.41% | 37.01% |
| EBITDA | 74.88% | 80.85% | 72.89% | 68.36% | 71.49% |
| EPS Basic | 11.33% | 20.05% | 32.15% | 33.61% | 39.64% |
| Normalized Basic EPS | 22.46% | 33.95% | 38.01% | 40.53% | 45.15% |
| EPS Diluted | 11.70% | 20.31% | 32.14% | 33.84% | 39.31% |
| Normalized Diluted EPS | 22.46% | 33.95% | 38.01% | 40.53% | 45.15% |
| Average Basic Shares Outstanding | 0.92% | 0.92% | 0.92% | 0.97% | 1.04% |
| Average Diluted Shares Outstanding | 0.92% | 0.92% | 0.92% | 0.97% | 1.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
